COR vs PSA · P/E 21, rev $321.33B vs rev $4.82B
Cencora Inc. (COR) versus PSA (PSA) — a side-by-side from cached financials, not a winner call.
Cencora Inc. (COR) is a medical distribution company listed on NYSE.
PSA (PSA) common stock.
Latest reported COR revenue for 2025-09-30 was $321.33B. Net income was $1.57B. Revenue was up 9.3% from 2024-09-30 to 2025-09-30. COR currently screens at market cap $53.91B and trailing P/E 21.2.
Latest reported PSA revenue for 2025-12-31 was $4.82B. Net income was $1.78B. Revenue was up 2.7% from 2024-12-31 to 2025-12-31. PSA currently screens at market cap $0.
COR currently screens at market cap $53.91B and trailing P/E 21.2. PSA currently screens at market cap $0.
Not investment advice. Open the COR and PSA stock pages for the full models.
Not investment advice.